Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice (Q37654789)

21 August 2017

1 reference

title

Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice (English)

1 reference

21 August 2017

2

Kris V Kowdley

1 reference

21 August 2017

Kristina M Utzschneider

series ordinal

1

1 reference

21 August 2017

1 January 2010

1 reference

Nature Reviews Endocrinology

21 August 2017

1 reference

21 August 2017

6

1 reference

21 August 2017

1

1 reference

21 August 2017

26-33

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2009.241

21 August 2017

0 references

cites work

Serum Ferritin Level Predicts Advanced Hepatic Fibrosis among U.S. Patients with Phenotypic Hemochromatosis

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Screening for hemochromatosis: recommendation statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Iron-mediated inhibition of mitochondrial manganese uptake mediates mitochondrial dysfunction in a mouse model of hemochromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Hemochromatosis: an endocrine liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Hemochromatosis mutations in the general population: iron overload progression rate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

A population-based study of the clinical expression of the hemochromatosis gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Iron-overload-related disease in HFE hereditary hemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Screening for hemochromatosis in asymptomatic subjects with or without a family history

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Clinical presentation of hemochromatosis: a changing scene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Predicting iron overload in hyperferritinemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Measurement and mapping of liver iron concentrations using magnetic resonance imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Hereditary haemochromatosis: a realistic approach to prevention of iron overload disease in the population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Population screening for haemochromatosis: a unifying analysis of published intervention trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Hereditary hemochromatosis: time for targeted screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

A targeted approach significantly increases the identification rate of patients with undiagnosed haemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Diagnosis and management of hemochromatosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Inherited iron loading: genetic testing in diagnosis and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Long-term survival in patients with hereditary hemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Declining prevalence of diabetes mellitus in hereditary haemochromatosis--the result of earlier diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Role of C282Y mutation in haemochromatosis gene in development of type 2 diabetes in healthy men: prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case - control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Oxidative status and malondialdehyde in beta-thalassaemia patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Increased insulin secretory capacity but decreased insulin sensitivity after correction of iron overload by phlebotomy in hereditary haemochromatosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.241

Factors determining glucose tolerance in patients with thalassemia major.

31 March 2020

1 reference

12 December 2020

HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis

1 reference

12 December 2020

Factors affecting glucose tolerance in hereditary hemochromatosis

1 reference

12 December 2020

Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis

1 reference

12 December 2020

Hereditary hemochromatosis: presentation and diagnosis in the 1990s

1 reference

12 December 2020

Long-term survival analysis in hereditary hemochromatosis

1 reference

12 December 2020

Venesection therapy in idiopathic haemochromatosis. An analysis of 40 treated and 18 untreated patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2009.241

1 reference

21 August 2017

1 reference

PubMed ID

20010968